We use our digital twin model to identify new targets, biomarkers and potential drug candidates
We discover innovative therapeutic strategies by exploring new combinations of druggable targets to address yet uncurable diseases
We simulate cell response to siRNA and CRISPR-Cas9 screening with our model to help experts understand mechanisms of drug resistance, sensitivity or synthetic lethality
We transform raw multi-omics data into actionable insights for experts in biology
